Belinostat
![]() | |
Clinical data | |
---|---|
Trade names | Beleodaq |
Other names | PXD101 |
AHFS/Drugs.com | beleodaq |
Routes of administration | Intravenous (IV) |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 100% (IV) |
Protein binding | 92.9–95.8%[1] |
Metabolism | UGT1A1 |
Excretion | Urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C15H14N2O4S |
Molar mass | 318.348 g/mol g·mol−1 |
3D model (JSmol) | |
| |
|
Belinostat (trade name Beleodaq, previously known as PXD101) is a histone deacetylase inhibitor drug developed by TopoTarget for the treatment of hematological malignancies and solid tumors.[2]
It was approved in July 2014 by the US FDA to treat peripheral T-cell lymphoma.[3]
In 2007 preliminary results were released from the Phase II clinical trial of intravenous belinostat in combination with carboplatin and paclitaxel for relapsed ovarian cancer.[4] Final results in late 2009 of a phase II trial for T-cell lymphoma were encouraging.[5] Belinostat has been granted orphan drug and fast track designation by the FDA,[6] and was approved in the US for the use against peripheral T-cell lymphoma on 3 July 2014.[3] It is not approved in Europe as of August 2014[update].[7]
The approved pharmaceutical formulation is given intravenously.[8]: 180 Belinostat is primarily metabolized by UGT1A1; the initial dose should be reduced if the recipient is known to be homozygous for the UGT1A1*28 allele.[8]: 179 and 181
References
- ^ "Beleodaq (belinostat) For Injection, For Intravenous Administration. Full Prescribing Information" (PDF). Spectrum Pharmaceuticals, Inc. Irvine, CA 92618. Retrieved 21 November 2015.
- ^ Plumb JA; Finn PW; Williams RJ; et al. (2003). "Pharmacodynamic Response and Inhibition of Growth of Human Tumor Xenografts by the Novel Histone Deacetylase Inhibitor PXD101". Molecular Cancer Therapeutics. 2 (8): 721–728. PMID 12939461.
- ^ a b "FDA approves Beleodaq to treat rare, aggressive form of non-Hodgkin lymphoma". FDA. 3 July 2014.
- ^ "CuraGen Corporation (CRGN) and TopoTarget A/S Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference". October 2007.
- ^ Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma, December 2009
- ^ "Spectrum adds to cancer pipeline with $350M deal". February 2010.
- ^ H. Spreitzer (4 August 2014). "Neue Wirkstoffe – Belinostat". Österreichische Apothekerzeitung (in German) (16/2014): 27.
- ^ a b Lexicomp, (corporate author) (2016). Bragalone, DL (ed.). Drug Information Handbook for Oncology (14th ed.). Wolters Kluwer. ISBN 9781591953517.
{{cite book}}
:|first1=
has generic name (help)